The stock of Antares Pharma, Inc. (NASDAQ:ATRS) has been Reiterated to Buy by H.C. Wainwright in its latest research note that was published on October 23. ATRS has given a price target of $3.50 by H.C. Wainwright, with other Wall Street analysts also giving their reports regarding the stock. H.C. Wainwright, analysts launched coverage of ATRS stock with a Buy rating, according to their flash note to investors on June 23.
Antares Pharma, Inc., which has current market capitalization of above $567 Million, published its last quarter earnings on June 30, 2019.
ATRS surged by $0.13 during the normal trading session on Thursday and reaching a high of $3.49 during the day while it closed the day at $3.48. The Antares stock had a low trading volume of 0.91 million shares on that day, which is low compared to the average daily volume of 1.17M shares. ATRS has also gained 8.07% of its value over the past 7 days. However, the stock has surged by 19.18% in the 3 months of the year. Over the past six months meanwhile, it has lost 3.60% while it has added 27.94% year-on date. Let us now take a look at the stock’s potential support and resistance levels. The publicly traded company was seen to have slipped by -0.29% from its 3 months high price. However, taking another look at ATRS will indicate that it is trading +23.4% away from its 90-day low. Looking at the bigger picture, the Antares Pharma, Inc. stock has dropped by -12.12% from its 52-week high while it has surged by +37.55% from its 52-week low price.
On May 01, 2019 GARRITY THOMAS J, Director sold 30000 shares of the company. The average price for that transaction was $2.67 per share, which meant that GARRITY THOMAS J earned $80100 selling the stocks. The sale was made public, with the document of the transaction filed with the SEC. Another insider trading occurred, with Director, JACOB LEONARD S selling 92078 shares of this stock on April 08, 2019. The average selling price for the stock was $3 per share, with the sold stock accruing $276234. Following this transaction, the Director JACOB LEONARD S now holds 331970 shares of the company, which is worth around $1115419.
Antares has around 40 Billion cash on their books at the moment. This figure will have to be compared and looked into, with their current liabilities standing at $26 Billion. The Antares stock is bringing in revenue of over 12 months, which is roughly 28 Billion. Despite all that, Antares Pharma, Inc. is seeing things progressing very much as their y-o-y quarterly revenue surged by 100.77%.
Looking at the stock’s Technical analysis information over the past 50 days shows that its Raw Stochastic average stood at 98.31%. This figure is better than the company’s 20-day Raw Stochastic average which currently stands at 97.67%. Over the past 20 days, Antares’s Stochastic %K stood at 79.38% while its Stochastic %D was revealed to be 61.91%.